SAB Interest Expense vs Operating Income Analysis

SABS Stock

USD 3.85 0.40 9.41%

SAB Biotherapeutics financial indicator trend analysis is much more than just breaking down SAB Biotherapeutics prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether SAB Biotherapeutics is a good investment. Please check the relationship between SAB Biotherapeutics Interest Expense and its Operating Income accounts. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in SAB Biotherapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of labor statistics.

For more information on how to buy SAB Stock please use our How to Invest in SAB Biotherapeutics guide.

Interest Expense vs Operating Income

Interest Expense vs Operating Income Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of SAB Biotherapeutics Interest Expense account and Operating Income. At this time, the significance of the direction appears to have very strong relationship.

The correlation between SAB Biotherapeutics' Interest Expense and Operating Income is 0.82. Overlapping area represents the amount of variation of Interest Expense that can explain the historical movement of Operating Income in the same time period over historical financial statements of SAB Biotherapeutics, assuming nothing else is changed. The correlation between historical values of SAB Biotherapeutics' Interest Expense and Operating Income is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Interest Expense of SAB Biotherapeutics are associated (or correlated) with its Operating Income. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Operating Income has no effect on the direction of Interest Expense i.e., SAB Biotherapeutics' Interest Expense and Operating Income go up and down completely randomly.

Correlation Coefficient

0.82

Relationship Direction	Positive
Relationship Strength	Strong

View All Relationships

Interest Expense

The cost incurred by an entity for borrowed funds, including loans, bonds, or lines of credit.

Operating Income

Operating Income is the amount of profit realized from SAB Biotherapeutics operations after accounting for operating expenses such as cost of goods sold (COGS), wages and depreciation. Operating income takes the gross income and subtracts other operating expenses and then removes depreciation. Operating Income of SAB Biotherapeutics is typically a synonym for earnings before interest and taxes (EBIT) and is also commonly referred to as operating profit or recurring profit. Earnings before interest and taxes (EBIT), representing the amount of profit a company generates from its operations.

Most indicators from SAB Biotherapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into SAB Biotherapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in SAB Biotherapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of labor statistics.

For more information on how to buy SAB Stock please use our How to Invest in SAB Biotherapeutics guide.At this time, SAB Biotherapeutics' Sales General And Administrative To Revenue is comparatively stable compared to the past year. Enterprise Value Over EBITDA is likely to gain to 0.35 in 2024, whereas Tax Provision is likely to drop 0.00 in 2024.

	2021	2022	2023	2024 (projected)
Depreciation And Amortization	1.7M	3.3M	3.7M	2.1M
Interest Income	23.1K	71.1K	130.8K	80.1K

Depreciation And Amortization Interest Income

SAB Biotherapeutics fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Net Tangible Assets	Property Plant And Equipment Net	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Long Term Debt	Cash And Short Term Investments	Net Receivables	Common Stock Shares Outstanding	Non Current Liabilities Total	Capital Lease Obligations	Other Current Assets	Other Stockholder Equity	Total Liab	Net Invested Capital	Property Plant And Equipment Gross	Short Long Term Debt	Total Current Assets	Capital Stock
Total Assets		-0.73	0.81	0.87	0.98	0.96	0.95	-0.87	-0.56	0.26	0.86	0.94	0.92	0.86	0.26	-0.95	-0.41	-0.32	0.83	0.88	0.69	0.98	1.0	-0.86	0.99	-0.65
Short Long Term Debt Total	-0.73		-0.66	-0.64	-0.71	-0.64	-0.76	0.86	0.87	0.3	-0.85	-0.76	-0.93	-0.85	0.33	0.68	0.39	0.86	-0.54	-0.82	-0.51	-0.72	-0.74	0.52	-0.68	0.8
Other Current Liab	0.81	-0.66		0.98	0.71	0.77	0.88	-0.64	-0.31	0.25	0.62	0.88	0.82	0.62	0.15	-0.78	-0.27	-0.24	0.96	0.57	0.88	0.7	0.83	-0.89	0.74	-0.37
Total Current Liabilities	0.87	-0.64	0.98		0.79	0.87	0.94	-0.66	-0.28	0.39	0.64	0.94	0.84	0.64	0.32	-0.87	-0.42	-0.18	0.95	0.6	0.82	0.79	0.88	-0.96	0.79	-0.37
Total Stockholder Equity	0.98	-0.71	0.71	0.79		0.97	0.93	-0.85	-0.57	0.3	0.83	0.93	0.9	0.83	0.32	-0.97	-0.52	-0.35	0.71	0.9	0.54	1.0	0.98	-0.81	0.96	-0.64
Net Tangible Assets	0.96	-0.64	0.77	0.87	0.97		0.97	-0.74	-0.41	0.48	0.73	0.97	0.86	0.73	0.47	-1.0	-0.62	-0.24	0.76	0.79	0.55	0.97	0.96	-0.9	0.91	-0.48
Property Plant And Equipment Net	0.95	-0.76	0.88	0.94	0.93	0.97		-0.76	-0.46	0.37	0.74	1.0	0.93	0.74	0.33	-0.98	-0.6	-0.36	0.83	0.78	0.64	0.93	0.95	-0.92	0.88	-0.5
Net Debt	-0.87	0.86	-0.64	-0.66	-0.85	-0.74	-0.76		0.86	0.2	-1.0	-0.76	-0.91	-1.0	0.16	0.74	0.22	0.58	-0.66	-0.9	-0.64	-0.85	-0.87	0.61	-0.89	0.94
Retained Earnings	-0.56	0.87	-0.31	-0.28	-0.57	-0.41	-0.46	0.86		0.59	-0.86	-0.46	-0.74	-0.86	0.54	0.43	0.12	0.86	-0.26	-0.81	-0.31	-0.58	-0.56	0.18	-0.59	0.95
Accounts Payable	0.26	0.3	0.25	0.39	0.3	0.48	0.37	0.2	0.59		-0.21	0.36	0.0	-0.21	0.98	-0.46	-0.53	0.6	0.28	-0.08	0.01	0.3	0.25	-0.56	0.2	0.49
Cash	0.86	-0.85	0.62	0.64	0.83	0.73	0.74	-1.0	-0.86	-0.21		0.74	0.9	1.0	-0.17	-0.73	-0.22	-0.57	0.65	0.88	0.63	0.83	0.86	-0.6	0.88	-0.94
Non Current Assets Total	0.94	-0.76	0.88	0.94	0.93	0.97	1.0	-0.76	-0.46	0.36	0.74		0.93	0.74	0.32	-0.98	-0.6	-0.37	0.82	0.79	0.64	0.93	0.95	-0.92	0.87	-0.5
Long Term Debt	0.92	-0.93	0.82	0.84	0.9	0.86	0.93	-0.91	-0.74	0.0	0.9	0.93		0.9	-0.02	-0.88	-0.46	-0.63	0.75	0.89	0.65	0.9	0.93	-0.76	0.87	-0.75
Cash And Short Term Investments	0.86	-0.85	0.62	0.64	0.83	0.73	0.74	-1.0	-0.86	-0.21	1.0	0.74	0.9		-0.17	-0.73	-0.22	-0.57	0.65	0.88	0.63	0.83	0.86	-0.6	0.88	-0.94
Net Receivables	0.26	0.33	0.15	0.32	0.32	0.47	0.33	0.16	0.54	0.98	-0.17	0.32	-0.02	-0.17		-0.45	-0.54	0.62	0.21	-0.06	-0.06	0.32	0.25	-0.51	0.22	0.42
Common Stock Shares Outstanding	-0.95	0.68	-0.78	-0.87	-0.97	-1.0	-0.98	0.74	0.43	-0.46	-0.73	-0.98	-0.88	-0.73	-0.45		0.66	0.29	-0.75	-0.79	-0.53	-0.96	-0.95	0.9	-0.89	0.48
Non Current Liabilities Total	-0.41	0.39	-0.27	-0.42	-0.52	-0.62	-0.6	0.22	0.12	-0.53	-0.22	-0.6	-0.46	-0.22	-0.54	0.66		0.27	-0.14	-0.31	0.16	-0.52	-0.41	0.52	-0.29	0.05
Capital Lease Obligations	-0.32	0.86	-0.24	-0.18	-0.35	-0.24	-0.36	0.58	0.86	0.6	-0.57	-0.37	-0.63	-0.57	0.62	0.29	0.27		-0.06	-0.62	-0.09	-0.36	-0.33	0.02	-0.28	0.67
Other Current Assets	0.83	-0.54	0.96	0.95	0.71	0.76	0.83	-0.66	-0.26	0.28	0.65	0.82	0.75	0.65	0.21	-0.75	-0.14	-0.06		0.55	0.95	0.7	0.84	-0.9	0.79	-0.4
Other Stockholder Equity	0.88	-0.82	0.57	0.6	0.9	0.79	0.78	-0.9	-0.81	-0.08	0.88	0.79	0.89	0.88	-0.06	-0.79	-0.31	-0.62	0.55		0.47	0.91	0.88	-0.53	0.9	-0.8
Total Liab	0.69	-0.51	0.88	0.82	0.54	0.55	0.64	-0.64	-0.31	0.01	0.63	0.64	0.65	0.63	-0.06	-0.53	0.16	-0.09	0.95	0.47		0.53	0.71	-0.72	0.69	-0.46
Net Invested Capital	0.98	-0.72	0.7	0.79	1.0	0.97	0.93	-0.85	-0.58	0.3	0.83	0.93	0.9	0.83	0.32	-0.96	-0.52	-0.36	0.7	0.91	0.53		0.97	-0.8	0.96	-0.64
Property Plant And Equipment Gross	1.0	-0.74	0.83	0.88	0.98	0.96	0.95	-0.87	-0.56	0.25	0.86	0.95	0.93	0.86	0.25	-0.95	-0.41	-0.33	0.84	0.88	0.71	0.97		-0.86	0.98	-0.65
Short Long Term Debt	-0.86	0.52	-0.89	-0.96	-0.81	-0.9	-0.92	0.61	0.18	-0.56	-0.6	-0.92	-0.76	-0.6	-0.51	0.9	0.52	0.02	-0.9	-0.53	-0.72	-0.8	-0.86		-0.79	0.31
Total Current Assets	0.99	-0.68	0.74	0.79	0.96	0.91	0.88	-0.89	-0.59	0.2	0.88	0.87	0.87	0.88	0.22	-0.89	-0.29	-0.28	0.79	0.9	0.69	0.96	0.98	-0.79		-0.7
Capital Stock	-0.65	0.8	-0.37	-0.37	-0.64	-0.48	-0.5	0.94	0.95	0.49	-0.94	-0.5	-0.75	-0.94	0.42	0.48	0.05	0.67	-0.4	-0.8	-0.46	-0.64	-0.65	0.31	-0.7

Click cells to compare fundamentals

SAB Biotherapeutics Account Relationship Matchups

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for SAB Stock Analysis

When running SAB Biotherapeutics' price analysis, check to measure SAB Biotherapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy SAB Biotherapeutics is operating at the current time. Most of SAB Biotherapeutics' value examination focuses on studying past and present price action to predict the probability of SAB Biotherapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move SAB Biotherapeutics' price. Additionally, you may evaluate how the addition of SAB Biotherapeutics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

SAB Interest Expense vs Operating Income Analysis

Interest Expense vs Operating Income

Interest Expense vs Operating Income Correlation Analysis

Correlation Coefficient

Interest Expense

Operating Income

SAB Biotherapeutics fundamental ratios Correlations

SAB Biotherapeutics Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Thematic Opportunities

Explore Investment Opportunities

Additional Tools for SAB Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Property Plant And Equipment Gross	+ 1.0	Total Assets
Net Invested Capital	+ 1.0	Total Stockholder Equity
Non Current Assets Total	+ 1.0	Property Plant And Equipment Net
Cash And Short Term Investments	+ 1.0	Cash
Total Current Assets	+ 0.99	Total Assets
Total Stockholder Equity	+ 0.98	Total Assets

Cash And Short Term Investments	- 1.0	Net Debt
Cash	- 1.0	Net Debt
Common Stock Shares Outstanding	- 1.0	Net Tangible Assets
Common Stock Shares Outstanding	- 0.98	Non Current Assets Total
Common Stock Shares Outstanding	- 0.98	Property Plant And Equipment Net
Common Stock Shares Outstanding	- 0.97	Total Stockholder Equity